Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression-Reference-Cited by-同舟云学术

Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression

Published:2006-10 Issue:4 Volume:68 Page:834-839
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Ryan Charles J.,Smith Alex,Lal Priti,Satagopan Jaya,Reuter Victor,Scardino Peter,Gerald William,Scher Howard I.

Publisher

Elsevier BV

Subject

Urology

Reference10 articles.

1. Randomized comparative study of 3 versus 8-month neoadjuvant therapy before radical prostatectomy: biochemical and pathological effects;Gleave;J Urol,2001

2. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial;Aus;BJU Int,2002

3. Neoadjuvant androgen ablation before radical prostatectomy in cT2bN×M0 prostate cancer: 5-year results;Soloway;J Urol,2002

4. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance;Holzbeierlein;Am J Pathol,2004

5. Natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy;Pound;JAMA,1999

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review;Current Medicinal Chemistry;2024-08

2. The roles of proteases in prostate cancer;IUBMB Life;2023-01-04

3. Prostate cancer histopathology using label-free multispectral deep-UV microscopy quantifies phenotypes of tumor aggressiveness and enables multiple diagnostic virtual stains;Scientific Reports;2022-06-04

4. High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice;iScience;2022-05

5. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy;European Urology Open Science;2021-12